GHRH analogue
Tesamorelin
Tesamorelin after one dose: 50% at ~26 min, 25% at 52 min, 12.5% at 78 min.
Drawn from the half-life in the app's model, ~26 min. The model's figures
- Compound
- Tesamorelin
- Symbol
- TES
- Family
- Growth hormone peptides
- Parts
- 15
- References
- 17
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

11%The 6th most tracked compound in Milligram: of people who track compounds in Milligram logged Tesamorelin in the last 90 days.
Schedule
Logged doses
Half of people logged between 1 and 2 mg per dose; the median was 1.5 mg.
Tracked alongside
The share of people logging Tesamorelin who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
Tesamorelin is a synthetic analogue of human growth hormone-releasing factor (GRF), also called growth hormone-releasing hormone (GHRH).2 It has the 44 amino acid sequence of human GRF with a hexenoyl group attached to the N-terminal tyrosine.2 FDA approved it in 2010 under the brand name Egrifta "for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy".2,4 Two formulations have current US labels, Egrifta SV (a 2 mg vial) and Egrifta WR (an 11.6 mg vial), and the Egrifta WR label states that the two "are not substitutable".3,2
The Egrifta WR label states that it is "not indicated for weight loss management as it has a weight neutral effect".2 Tesamorelin is named as a growth hormone-releasing hormone analogue in the World Anti-Doping Agency's 2026 Prohibited List.6 Tesamorelin carries the app's own grade of "Strong Evidence"; FDA's 2010 summary review states that "clinical benefit of a reduction in VAT remains uncertain" (VAT is visceral adipose tissue).4
How it works
Sources in this part
The Egrifta WR label states that in laboratory tests tesamorelin "binds and stimulates human GRF receptors with similar potency as the endogenous GRF".2 GRF acts on pituitary somatotroph cells "to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH)," and tesamorelin stimulates GH secretion and subsequently increases IGF-1 and IGFBP-3 levels.2
FDA's 2010 summary review states that the hexenoyl group at the N-terminus was added "to extend its half-life while retaining its biological activity".4
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~26 min
- Bioavailability
- 4%
- Typical dose
- 1,280–2,000 mcg/day
- Route
- SubQ
- Time to peak
- ~15 min
| Measure | App's figure | Source's figure |
|---|---|---|
| Half-life | ~26 minutes | 26 minutes in healthy subjects and 38 minutes in people with HIV without lipodystrophy after 14 consecutive days of 2 mg daily (2010 label); 11 minutes after one 1.28 mg dose of Egrifta WR and 8 minutes after one 1.4 mg dose of Egrifta SV in healthy subjects1,2,3 |
| Bioavailability | 4% | Absolute bioavailability under 4% after a 2 mg subcutaneous dose of the original 1 mg per vial formulation in healthy adults2 |
| Time to peak | ~15 minutes | Median peak plasma concentration time of 0.15 hours (9 minutes) in healthy subjects and in people with HIV without lipodystrophy2 |
The labels report that tesamorelin exposure (AUC) was 34% higher in people with HIV without lipodystrophy than in healthy subjects, with a similar peak concentration.2 A 2015 population analysis by González-Sales and colleagues in Clinical Pharmacokinetics, of 38 people with HIV and healthy subjects, used a one-compartment model with first- and zero-order absorption.7
The chart below is an illustration from the app's 26-minute half-life and 15-minute time to peak, with the once-daily interval the labels describe, not measured concentrations.2 The current labels give 11 and 8 minutes after single doses, so the curve would fall faster on those figures.2,3
Level over 3 days
Level, as a share of the peak after one 1.28 mg dose
As studied: every day2. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).
An illustration from a pharmacokinetic model using a half-life of 0.43 hours. It is not a measured level or a suggested dose.
Human studies
The Egrifta WR label's primary efficacy assessment was the percent change in visceral adipose tissue (VAT) at week 26 on a CT scan at the L4-L5 vertebral level.2 Theratechnologies, which makes tesamorelin, sponsored the two phase 3 trials.8
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Falutz and colleagues, 2007 (NEJM)9,8 | Randomised, placebo-controlled; Study 1 of the two phase 3 trials that Theratechnologies sponsored | 412 people with HIV and abdominal fat accumulation, 86% men | 2 mg subcutaneous daily, 26 weeks | VAT fell 15.2% on tesamorelin and rose 5.0% on placebo (P<0.001); adverse events did not differ significantly, but more people on tesamorelin withdrew because of one; no significant differences in glycaemic measures; triglycerides fell 50 mg/dL against a rise of 9 and IGF-I rose 81.0% against a fall of 5.0% (P<0.001); FDA's review describes the lipid and body image changes across the two pivotal studies as not robust or consistent4 |
| Falutz and colleagues, 2010 (JCEM)11 | Pooled analysis of the two phase 3 trials; author Mamputu is a Theratechnologies employee per later disclosures8,13 | 806 people with HIV in the pooled report: 543 on tesamorelin, 263 on placebo (the label counts 412 plus 404 in the two trials, and the EMA page 816) | 2 mg subcutaneous daily, 26 weeks, then 26 weeks of extension | At week 26 VAT changed by -24 cm2 against +2 cm2 (treatment effect -15.4%); at week 52 the group continuing tesamorelin kept a VAT fall of 35 cm2 (17.5%) against original baseline, in an extension FDA described as limited by the absence of an appropriate comparator;4 triglycerides -37 against +6 mg/dL and belly appearance distress (P=0.002) also improved at week 26, measures FDA's review describes as not robust or consistent4 |
| Stanley and colleagues, 2014 (JAMA)12 | Randomised, double-blind, placebo-controlled; one hospital; National Institutes of Health funded, drug supplied by Theratechnologies | 54 randomised (the paper's text says 50), 50 at baseline assessment and 48 treated, all with HIV and abdominal fat accumulation | 2 mg subcutaneous daily, 6 months | VAT -34 cm2 against +8 cm2 (treatment effect -42 cm2, P=0.005); liver fat -2.0 against 0.9 lipid-to-water % (median change, P=0.003); fasting glucose +9 against +2 mg/dL at 2 weeks (P=0.03), not different at 6 months (P=0.56); HbA1c rose 0.20 against 0.02 percentage points over 6 months (treatment effect 0.19, P=0.03) |
| Clemmons and colleagues, 2017 (PLoS One)13 | Randomised, placebo-controlled; sponsored by Theratechnologies, which employs author Mamputu; author Clemmons received consultancy fees from it | 53 people with type 2 diabetes (16 placebo, 18 on 1 mg, 19 on 2 mg) | 1 or 2 mg subcutaneous daily, 12 weeks | At week 12 no significant difference between groups in relative insulin response, fasting glucose or HbA1c, though HbA1c rose slightly from baseline in the 2 mg group and its fasting glucose rose from baseline at weeks 4 and 8; no one stopped for loss of diabetes control; the authors call the sample size relatively small |
| Stanley and colleagues, 2019 (Lancet HIV)14 | Randomised 1:1, double-blind, multicentre, placebo-controlled; National Institutes of Health funded, drug supplied by Theratechnologies at a reduced cost | 61 people with HIV and hepatic fat fraction of 5% or more at baseline assessment; 26 on tesamorelin and 28 on placebo in the primary analysis | 2 mg subcutaneous daily, 12 months, then 6 months open-label for all | Hepatic fat fraction: absolute effect size -4.1% against placebo (95% CI -7.6 to -0.7, P=0.02); glucose parameters did not differ; more localised injection site complaints on tesamorelin; serious adverse events did not differ by arm |
| Ellis and colleagues, 2025 (J Infect Dis)15 | Phase 2 randomised open-label trial against standard of care, no placebo; all authors report no conflicts | 73 virally suppressed people with HIV and abdominal obesity, randomised 3:2 | 2 mg subcutaneous daily, 6 months | Neurocognitive change did not differ between groups (P=.673); waist circumference fell more on tesamorelin (median difference -2.7 cm, P=.015); the authors cite insufficient power |
Deeper analysis: the two phase 3 trials (Falutz and colleagues, 2007 and 2010)
The US label describes two multicentre, randomised, double-blind, placebo-controlled studies in HIV-infected patients with lipodystrophy and excess abdominal fat: Study 1 (NCT00123253, 412 people) and Study 2 (NCT00435136, 404 people).2 People were randomised 2 to 1 to 2 mg of tesamorelin or placebo daily for 26 weeks; inclusion required age 18 to 65 years, set waist and waist-to-hip thresholds and fasting blood glucose below 150 mg/dL, and exclusions included type 1 and type 2 diabetes, previous treatment with insulin or oral hypoglycemic or insulin-sensitizing agents, history of malignancy and hypopituitarism.2 At 26 weeks VAT changed by -27 cm2 on tesamorelin against +4 cm2 on placebo in Study 1 (difference -31 cm2, 95% CI -39 to -24) and by -21 cm2 against 0 in Study 2 (difference -21 cm2, 95% CI -29 to -12).2 Analyses used the intent-to-treat population with the last observation carried forward, and 26-week completion was 80% in Study 1 and 74% in Study 2.2 The label's percent changes (-18% against +2% in Study 1, -14% against -2% in Study 2) come from a statistical model of the log of VAT, so they differ from paper figures such as 15.2% against 5.0%.2,9
FDA's 2010 summary review states that "Egrifta clearly met its primary efficacy endpoint in two pivotal studies," but that "the significant reductions in VAT were not accompanied by robust or consistent changes in secondary supportive efficacy measures of improved patient's self-perception of body image or lipid abnormalities".4 It states that "clinical benefit of a reduction in VAT remains uncertain and if present is likely realized in only a subset of HIV patients with lipodystrophy," that the extension phase was "somewhat limited by the absence of an appropriate comparator," and that for patients discontinuing tesamorelin "there was no durability of effect".4 The review gives serious adverse events as 3.7% on tesamorelin and 4.2% on placebo, discontinuation for an adverse event during the main phase as 9.6% against 6.1%, and hypersensitivity reactions in 27 tesamorelin-treated patients against 1 on placebo.4 It counts 4 deaths in the HIV program (3 on tesamorelin, 1 on placebo) and 6 in the non-HIV program (5 on tesamorelin, 1 on placebo), with "too few deaths overall to make any definitive conclusions," and states that "the most compelling evidence of benefit came from patient testimonials during the open public hearing at the advisory committee".4
The authors of a 2015 analysis of the same trials, including Falutz, write that "the study population consisted largely of white male patients, our findings may not apply to other ethnicities or to women".8 The exploratory analyses in the 2015 paper were sponsored and conducted by EMD Serono, Inc., which employs two of its authors; its disclosures also state that Jean-Claude Mamputu, an author of both 2010 reports, is employed by Theratechnologies and has stock or share options in it, and that Falutz has received consultancy fees from Theratechnologies and payment for lectures from Serono, USA, and ViiV, Canada.8,10,11 Steven Grinspoon, an author of the 2007 and 2010 reports, states in the 2019 Lancet HIV paper that he has served on the scientific advisory board of and as a consultant to Theratechnologies.14
Deeper analysis: Stanley and colleagues, JAMA, 2014
The trial, at Massachusetts General Hospital, had visceral adipose tissue and liver fat as its two primary end points; of 76 people screened, the paper's summary gives 54 randomised and its text gives 50 randomised, to 2 mg daily or placebo for 6 months; 50 attended the baseline assessment and 48 received study drug.12 Visceral fat fell by a mean of 34 cm2 on tesamorelin and rose by 8 cm2 on placebo, and the median change in liver fat was -2.0 against 0.9 lipid-to-water percent, a net effect of -2.9.12 Fasting glucose rose 9 against 2 mg/dL at 2 weeks (P=0.03) and did not differ at 6 months, and the paper calls the rise in HbA1c over 6 months, 0.20 against 0.02 percentage points (treatment effect 0.19, 95% CI 0.01 to 0.36, P=0.03), "slight but statistically significant".12 There were three serious adverse events in each arm: on tesamorelin, hospitalisations for exacerbation of existing congestive heart failure and for pneumonia, and a basal cell carcinoma in a person with a prior history of it; on placebo, hospitalisations for acute stroke and for Heller myotomy, and a basal cell carcinoma likewise.12
The authors write that the study "may have been underpowered to detect changes in secondary endpoints," that "the clinical significance of our data is not known," and that liver biopsies were not performed.12 Funding came from the National Institutes of Health; study drug was provided by Theratechnologies, which the paper says had no role in design, conduct, analysis or the decision to submit, but "reviewed the manuscript prior to submission".12 The last-listed author, Grinspoon, discloses consulting for several companies and "investigator initiated research funds from Theratechnologies, Inc" for projects unrelated to this one.12
Deeper analysis: Stanley and colleagues, Lancet HIV, 2019
This multicentre trial in people with HIV and a hepatic fat fraction of 5% or more on magnetic resonance spectroscopy randomised participants 1:1 to 2 mg daily or identical placebo for 12 months, followed by 6 months of open-label tesamorelin for all.14 The absolute effect size on hepatic fat fraction was -4.1% against placebo (95% CI -7.6 to -0.7, P=0.02), a relative change from baseline of -37% (95% CI -67 to -7), in an analysis of 26 people on tesamorelin and 28 on placebo.14 In the biopsy-based secondary end points, fibrosis progressed in 2 people on tesamorelin (10.5%) against 9 on placebo (37.5%, P=0.04; the percentages imply group sizes of 19 and 24, which the text does not state), but tesamorelin did not improve existing fibrosis and did not significantly change the NAS score.14 Two people on tesamorelin, one with diabetes at baseline, stopped for worsening hyperglycaemia, among four on tesamorelin and one on placebo with events that met protocol criteria for investigator discontinuation (P=0.17); four people on tesamorelin and two on placebo were hospitalised with serious adverse events, which did not differ by arm and none of which was judged related to the study drug.14
The authors write that the study "was not designed as a therapeutic trial for NASH, not all patients had significant steatohepatitis," so effects on the histological end points FDA recommends for late-stage steatohepatitis trials could not be assessed definitively, and that whether effects last beyond treatment needs study.14 The paper states that the authors were solely responsible for the hypothesis, design, analysis and decision to submit, and that Theratechnologies provided study drug at a reduced cost and, by contract, received serious adverse event reports and notice of intent to submit for publication. The study was funded by the National Institutes of Health and its National Institute of Allergy and Infectious Diseases.14 Grinspoon is also named as an inventor on a patent application on the effects of tesamorelin in the treatment of hepatic disease.14
Doses reported in studies and on labels
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Egrifta WR label (adults with HIV and lipodystrophy)2 | 1.28 mg | Once daily, subcutaneous | No length given |
| Egrifta SV label (adults with HIV and lipodystrophy)3 | 1.4 mg | Once daily, subcutaneous | No length given |
| Original Egrifta label, 2010 (people with HIV and lipodystrophy)1 | 2 mg | Once daily, subcutaneous | No length given |
| Dose-finding trial summarised by FDA, 2010 (HIV lipodystrophy, against placebo)4 | 1 mg or 2 mg | Daily | 12 weeks |
| Clemmons and colleagues, 2017 (type 2 diabetes, against placebo)13 | 1 mg or 2 mg | Once daily, subcutaneous | 12 weeks |
| Stanley and colleagues, 2019 (HIV and hepatic fat of 5% or more, against placebo)14 | 2 mg | Once daily, subcutaneous | 12 months, then 6 months open-label |
Side effects reported
Sources in this part
The Egrifta WR label lists the most commonly reported adverse reactions (over 5%) as "arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema, and myalgia".2 The label reports injection site reactions in 25% of tesamorelin-treated patients and 14% of placebo-treated patients over the first 26 weeks, and hypersensitivity reactions in 4% of patients.2
The label describes fluid retention, with edema, arthralgia and carpal tunnel syndrome, that "are either transient or resolve with discontinuation of treatment".2 It states that treatment can result in glucose intolerance: HbA1c of 6.5% or more at week 26 occurred in 5% on tesamorelin and 1% on placebo, with a hazard odds ratio for diabetes of 3.3 (CI 1.4 to 9.6).2 The label also records contraindications in people with disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity, and pregnancy.2 In the label's animal data, tesamorelin acetate given to rats during organogenesis and lactation resulted in hydrocephaly in offspring at about two and four times the clinical dose, respectively, and rabbits showed no adverse developmental effects at up to about 500 times the clinical dose.2 The label's warnings also cover an increased risk of neoplasms, which it bases on "the increased background risk of malignancies in HIV-positive patients" and on growth hormone being "a known growth factor", with a history of malignancy to be weighed before starting. They also cover increased mortality in acute critical illness, which the label says "has been reported after treatment with pharmacologic amounts of growth hormone", with a statement that discontinuation be considered in critically ill patients, and monitoring of patients with diabetes for development or worsening of retinopathy.2
Bloodwork and markers
Sources in this part
The app lists IGF-1, blood glucose and insulin as markers for tesamorelin. The Egrifta WR label includes a warning that "EGRIFTA WR stimulates GH production and increases serum IGF-1," and its warnings direct prescribers to monitor IGF-1 levels during therapy and to evaluate glucose status before starting.2 Among patients treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3.2
Regulatory and anti-doping status
FDA approved tesamorelin in 2010 for "the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy".2 In its 2010 summary review FDA wrote that an advisory committee panel "voted unequivocally in favor of approval," and that approval based on VAT reduction in this limited population "is not an FDA endorsement of this endpoint as a validated surrogate for drug approval in other highly prevalent conditions (e.g., metabolic syndrome, obesity, atherosclerosis)".4
The European Medicines Agency page states that its Committee for Medicinal Products for Human Use (CHMP) "was of the provisional opinion that Egrifta could not have been approved" at the time of the withdrawal in 2012.5 Its stated reasons included that "the reduction has not been shown to be clinically meaningful in terms of actual health benefits to patients," that trial participants "were not representative of European HIV patients," and that high IGF-1 levels "may be associated with an increased risk of cancer and a potential worsening of diabetic eye disease," which the committee considered a major safety concern.5
The WADA 2026 Prohibited List, in effect from 1 January 2026, names tesamorelin in section S2.2.4 as an example of growth hormone-releasing hormone analogues.6 Section S2 is prohibited at all times, in and out of competition, and its substances are non-specified substances.6 A 2026 study by Colpaert and colleagues in Drug Testing and Analysis, which lists a WADA grant, gave Egrifta to six healthy volunteers for 10 consecutive days, with no dose given in the paper's summary, and reported that tesamorelin use could not be detected in post-administration urine despite a urine limit of detection of 13 pg/mL that it describes as "70 times lower than the WADA minimum required performance level".16 In serum, metabolites were detected in all six volunteers for up to 2 hours after injection, and intact tesamorelin in two volunteers for up to 30 minutes.16 Its authors report a short detection window for tesamorelin and conclude that testing methods "focus on metabolites in serum, rather than intact compounds in urine".16
Storage and handling
Sources in this part
The Egrifta WR label states that the 11.6 mg vial is stored at room temperature at 20 to 25 degrees Celsius, with excursions permitted to 15 to 30 degrees Celsius.2 The same label gives "Do not freeze" for the reconstituted solution and for the injection box.2 The Egrifta SV label gives the same room temperature range for its 2 mg vial and states "Do not freeze or refrigerate the reconstituted solution".3 FDA's 2010 review of the original formulation states that the medication box "must be refrigerated" and gives a shelf life of 24 months stored at 2 to 8 degrees Celsius.4
What is not known
Sources in this part
The Egrifta WR label states that long-term cardiovascular safety has not been established and that the effects of prolonged IGF-1 elevation are unknown.2 The labels state that there is no information on use in patients older than 65 years.2 The authors' own limitation statements for the 2007 and 2010 phase 3 reports are not given here because their full texts were not available. The phase 3 trials were run before integrase inhibitors were introduced, and a 2024 subgroup analysis of 31 completers on those regimens is small, with its authors writing that they lacked power to examine specific regimens.2,17
Frequently asked questions
What is the half-life of tesamorelin?
The app lists a half-life of about 26 minutes for tesamorelin, which matches the 2010 FDA label's 26 minutes in healthy subjects.1 The same label gave 38 minutes in people with HIV without lipodystrophy, and the current Egrifta WR and Egrifta SV labels give 11 and 8 minutes after single doses in healthy subjects.1,2,3
What is the bioavailability of tesamorelin?
The labels report an absolute subcutaneous bioavailability of less than 4% in healthy adults after a 2 mg dose of the original formulation, and the app lists 4%.2
What is tesamorelin approved for?
FDA approved tesamorelin (Egrifta) in 2010 for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.2
Is tesamorelin approved in Europe?
The European Medicines Agency page records that Ferrer Internacional, S.A. notified the Committee for Medicinal Products for Human Use (CHMP) on 21 June 2012 that it wishes to withdraw its marketing authorisation application for Egrifta, and that at the time of the withdrawal the CHMP was of the provisional opinion that it could not have been approved.5
Is tesamorelin banned by WADA?
The WADA 2026 Prohibited List names tesamorelin in section S2.2.4 among growth hormone-releasing hormone analogues, and section S2 is prohibited at all times, in and out of competition.6
How much visceral fat did tesamorelin reduce in trials?
In the pooled analysis of the two phase 3 trials, which Theratechnologies sponsored, VAT changed by -24 cm2 on tesamorelin against +2 cm2 on placebo at 26 weeks, a treatment effect of -15.4%.11,8 The Egrifta WR label gives -27 against +4 cm2 in Study 1 and -21 against 0 cm2 in Study 2.2 FDA's 2010 summary review states that the "clinical benefit of a reduction in VAT remains uncertain".4
What are the side effects of tesamorelin?
The Egrifta WR label lists arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema and myalgia as the most commonly reported adverse reactions.2 It reports injection site reactions in 25% of tesamorelin-treated patients against 14% on placebo over the first 26 weeks, hypersensitivity reactions in 4% of treated patients, and HbA1c of 6.5% or more at week 26 in 5% on tesamorelin against 1% on placebo.2
Guides, tools and comparisons
- Tesamorelin dosageA guide that answers a question on this compound.
- Calculator for TesamorelinA calculator set up for this compound.
- Ipamorelin vs tesamorelinA side-by-side with another compound.
- Sermorelin vs tesamorelinA side-by-side with another compound.
- Previous in Growth hormone peptides: Sermorelin + IpamorelinThe compound before this one in the class.
- Next in Growth hormone peptides: Tesamorelin + IpamorelinThe compound after this one in the class.
References
- US Food and Drug Administration. EGRIFTA (tesamorelin for injection) prescribing information, NDA 022505, revised November 2010. FDA label (2010)
- Theratechnologies Inc. EGRIFTA WR (tesamorelin) for injection, full prescribing information. DailyMed, US National Library of Medicine, label revised March 2025. DailyMed label (Egrifta WR)
- Theratechnologies Inc. EGRIFTA SV (tesamorelin) for injection, full prescribing information. DailyMed, US National Library of Medicine, label revised March 2024. DailyMed label (Egrifta SV)
- Parks MH. Division Director Summary Review, NDA 22-505, Egrifta (tesamorelin acetate). FDA Center for Drug Evaluation and Research, 5 November 2010. FDA summary review (2010)
- European Medicines Agency. Egrifta (tesamorelin): withdrawal of application. EMA, page last updated 18 July 2012. EMA page
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA, 2026. WADA list 2026
- González-Sales M, et al. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet 2015. PMID 25358450
- Mangili A, et al. Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. PLoS One 2015. PMC4601733
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007. PMID 18057338
- Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010. PMID 20101189
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010. PMID 20554713
- Stanley TL, et al. Effect of tesamorelin on liver fat and visceral fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 2014. PMC4363137
- Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One 2017. PMC5472315
- Stanley TL, et al. Effects of tesamorelin on nonalcoholic fatty liver disease in HIV: a randomized, double-blind, multicenter trial. Lancet HIV 2019. PMC6981288
- Ellis RJ, et al. Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. J Infect Dis 2025. PMID 39813152
- Colpaert T, et al. Detecting GHRH analogue tesamorelin and its metabolites in post-administration human urine and serum using LC-HRMS/MS. Drug Test Anal 2026. PMID 43013893
- Russo SC, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS 2024. PMC11365754